@entity1863 plus @entity3118 compared with @entity1863 plus @entity786 as a conditioning regimen prior to hematopoietic stem cell transplantation in XXXX with @entity1583 : a meta-analysis.

@entity1 @entity137 @entity786 @entity102 @entity3118 @entity2132 @entity1583 @entity1863 @entity1349
OBJECTIVES: The aim of the article is to critically appraise and synthesize available evidence regarding the efficacy and regimen-related @entity137 (RRT) of @entity1863 plus @entity3118 (BuFlu) compared to @entity1863 plus @entity786 (BuCy) as a conditioning regimen, prior to allogeneic hematopoietic stem cell transplantation (HSCT) in @entity1 with @entity1583 . METHODS: A meta-analysis was attempted on clinical controlled trials (CCTs), randomized or non-randomized controlled trials (RCTs or non-RCTs), comparing BuCy with BuFlu. We did a systematic search of the indexed medical literature using appropriate keywords to identify potentially relevant articles. The primary outcome of interest was efficacy measured by @entity1349 ( @entity1349 ) and event-free survival (EFS), @entity2132 ( @entity2132 ). @entity102 (extensive) and other @entity137 were secondary endpoints. A relative risk or risk ratio (RR) and 95% confidence interval (CI) was calculated for each outcome in the meta-analysis. RESULTS: Nine clinical controlled trials were included, of which 4 tries were RCTs involving 584 @entity1 and the other 5 were non-RCTs involving 571 @entity1 . The cumulative incidences of @entity1349 , EFS, @entity2132 ( @entity2132 ) were not significantly different between the two regimens. The non-relapse mortality was higher in BuCy but non-significant increment (RR=1.48, 95% CI: [0.97-2.26]). Liver related @entity137 was significantly higher with BuCy compared to BuFlu (RR=1.90, 95% CI: [1.00-3.61]). CONCLUSION: Liver related @entity137 is significantly lesser with BuFlu, but BuFlu regimen has no significant benefits compared with BuCy in @entity1349 , EFS, @entity2132 . For all this, the weight of evidence favors BuFlu over BuCy as a first choice-conditioning regimen for @entity1 with @entity1583 , especially for @entity1 who have poor liver function.
